Work

Supplementary Figure 3 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 3. Drug naive U87 or panobinostat-resistant, bortezomib-resistant, or panobinostat and bortezomib-resistant (P + B) cells were cotreated with panobinostat (25 nmol/L) plus bortezomib (2.5 nmol/L) for 24 h.

DOI: 10.1158/1541-7786.22514085.v1

Authors: Esther P. Jane, Daniel R. Premkumar, Swetha Thambireddy, Brian Golbourn, Sameer Agnihotri, Kelsey C. Bertrand, Stephen C. Mack, Max I. Myers, Ansuman Chattopadhyay, D. Lansing Taylor, Mark E. Schurdak, Andrew M. Stern, Ian F. Pollack

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362536282

Cites:

Cited by:

Related to: 10